Trial Profile
A Phase III, Open-label, Single Centre, Single-arm, Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Raltegravir
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 08 Jun 2012 Planned end date changed from 1 Apr 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 27 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Sep 2010 New trial record